Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
Local application
29/03/2023
Indication
In combination with bendamustine for first-line treatment of chronic lymphocytic leukaemia.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
-
Comments
-